Tumor lysis with LTX-401 creates anticancer immunity
文献类型：期刊论文
| 作者 | Xie, Wei1,2,3,4; Mondragon, Laura1,2,3,4; Mauseth, Brynjar5,6,7; Wang, Yan1,2,3,4; Pol, Jonathan1,2,3,4; Levesque, Sarah1,2,3,4; Zhou, Heng1,2,3,4,8; Yamazaki, Takahiro9,10,11,12,13; Eksteen, Johannes J.14; Zitvogel, Laurence9,10,11,12 |
| 刊名 | ONCOIMMUNOLOGY
 |
| 出版日期 | 2019-04-12 |
| 页码 | 8 |
| 关键词 | Oncolysis anticancer therapy immunogenic cell death checkpoint blockade |
| ISSN号 | 2162-402X |
| DOI | 10.1080/2162402X.2019.1594555 |
| 通讯作者 | Kepp, Oliver(captain.olsen@gmail.com) |
| 英文摘要 | Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and that sequential local inoculation of LTX-401 was able to cure immunocompetent host from subcutaneous MCA205 and TC-1 cancers. Cured animals exhibited long-term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors. Nevertheless, the local treatment with LTX-401 alone had only limited abscopal effects on secondary contralateral lesions. Anticancer effects resulting from single as well as sequential injections of LTX-401 were boosted in combination with PD-1 and CTLA-4 immune checkpoint blockade (ICB), and sequential LTX-401 treatment combined with double ICB exhibited strong abscopal antineoplastic effects on contralateral tumors underlining the potency of this combination therapy. |
| 收录类别 | SCI |
| WOS关键词 | ONCOLYTIC PEPTIDE ; LTX-315 ; CANCER |
| WOS研究方向 | Oncology ; Immunology |
| WOS类目 | Oncology ; Immunology |
| 语种 | 英语 |
| WOS记录号 | WOS:000466670400001 |
| 出版者 | TAYLOR & FRANCIS INC |
| URI标识 | http://www.irgrid.ac.cn/handle/1471x/2555486 |
| 专题 | 寒区旱区环境与工程研究所 |
| 通讯作者 | Kepp, Oliver |
| 作者单位 | 1.Gustave Roussy Comprehens Canc Inst, Metabol & Cell Biol Platforms, Villejuif, France 2.INSERM, Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France 3.Univ Paris 05, Sorbonne Paris Cite, Paris, France 4.Univ Paris 06, Paris, France 5.Lytix Biopharma, Oslo, Norway 6.Oslo Univ Hosp, Rikshosp, Div Canc Surg & Transplantat, Oslo, Norway 7.Univ Oslo, Inst Clin Med, Oslo, Norway 8.Chinese Acad Sci, Inst Modern Phys, Lanzhou, Gansu, Peoples R China 9.Gustave Roussy Comprehens Canc Ctr, Villejuif, France 10.Univ Paris Sud XI, Le Kremlin Bicetre, France |
| 推荐引用方式 GB/T 7714 | Xie, Wei,Mondragon, Laura,Mauseth, Brynjar,et al. Tumor lysis with LTX-401 creates anticancer immunity[J]. ONCOIMMUNOLOGY,2019:8. |
| APA | Xie, Wei.,Mondragon, Laura.,Mauseth, Brynjar.,Wang, Yan.,Pol, Jonathan.,...&Kroemer, Guido.(2019).Tumor lysis with LTX-401 creates anticancer immunity.ONCOIMMUNOLOGY,8. |
| MLA | Xie, Wei,et al."Tumor lysis with LTX-401 creates anticancer immunity".ONCOIMMUNOLOGY (2019):8. |
入库方式： iSwitch采集
来源：寒区旱区环境与工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。